Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology and international markets. Core operating profit rose 33% to ¥229 billion.

Narrow-moat Daiichi Sankyo’s third-quarter earnings were ... However, it depends on the continued momentum of Enhertu, which remains strong so far. We expect multiple key data readouts this ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective ...

In the Japan business unit, sales of Lixiana, a direct oral anticoagulant; Tarlige analgesic; and ENHERTU, an anti-cancer agent increased as did the sales of Daiichi Sankyo Healthcare, while again ...

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive ...

leading to three of the largest licensing deals in history along with the approvals of ENHERTU® and DATROWAY®, two precision cancer medicines invented with Daiichi Sankyo’s DXd ADC Technology ...